Healthcare Services Group Inc
HCSG Nasdaq Services-Nursing & Personal Care Facilities Financials FY2016βFY2025
What Healthcare Services Group Inc does
No business description yet.
- Legal name
- HEALTHCARE SERVICES GROUP INC
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 13, 2026
- Accession Β· CIK
- 0000731012-26-000009
0000731012
Revenue and margins
Healthcare Services Group Inc had $1.8B of revenue in fiscal 2025, up 7.1% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew β2.8% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $139M in fiscal 2025, 7.6% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Healthcare Services Group Inc returned $61.6M to shareholders in fiscal 2025, 44% of free cash flow. The diluted share count fell 1.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Healthcare Services Group Inc can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $185M | $121M | $147M | $107M | $168M |
| Current ratio | 2.9x | 2.7x | 2.6x | 2.9x | 3.4x |
| Quick ratio | 2.9x | 2.7x | 2.6x | 2.9x | 3.3x |
| Total assets | $780M | $721M | $791M | $803M | $794M |
| Total liabilities | $332M | $303M | $334M | $303M | $284M |
| Shareholders' equity | $445M | $418M | $457M | $500M | $510M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 4 / 8 | 6 / 8 | 6 / 8 | 2 / 8 | 3 / 8 | 6 / 8 | 7 / 8 | 7 / 8 |
| Accruals ratio | 6.8% | 13.4% | 0.5% | β4.1% | β15.7% | 1.5% | 5.7% | β0.7% | 1.1% | β10.8% |
| Altman Z'' | β | β | β | β | β | β | β | β | β | β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.6B | $1.9B | $2.0B | $1.8B | $1.8B | $1.6B | $1.7B | $1.7B | $1.7B | $1.8B |
| Gross profit | $223M | $251M | $234M | $228M | $268M | $231M | $193M | $215M | $228M | $239M |
| Interest expense | β | $1.4M | $3.1M | $3.5M | β | β | β | β | β | β |
| Pretax income | $120M | $133M | $99.9M | $85.1M | $129M | $65.5M | $44.6M | $53.1M | $52.9M | $67.9M |
| Income tax | $43.0M | $44.7M | $16.4M | $20.5M | $30.5M | $17.0M | $10.3M | $14.7M | $13.5M | $8.8M |
| Net income | $77.4M | $88.2M | $83.5M | $64.6M | $98.7M | $48.5M | $34.2M | $38.4M | $39.5M | $59.1M |
| Diluted EPS | $1.05 | $1.19 | $1.12 | $0.87 | $1.32 | $0.65 | $0.46 | $0.52 | $0.53 | $0.81 |
| Diluted shares | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B |
| Cash flow | ||||||||||
| Cash from operations | $41.4M | $7.6M | $80.0M | $93.6M | $217M | $37.1M | β$8.2M | $43.5M | $30.8M | $145M |
| Capital expenditure | $5.4M | $5.4M | $4.9M | $4.4M | $4.3M | $5.7M | $5.2M | $5.4M | $6.3M | $5.8M |
| Free cash flow | $36.0M | $2.2M | $75.1M | $89.2M | $213M | $31.4M | β$13.4M | $38.1M | $24.5M | $139M |
| Depreciation and amortization | $7.5M | $8.9M | $9.3M | $13.9M | $14.3M | $14.7M | $15.3M | $14.3M | $14.6M | $16.8M |
| Stock-based compensation | $4.3M | $6.0M | $5.9M | $6.9M | $7.9M | $8.8M | $9.2M | $9.0M | $9.2M | $12.0M |
| Share buybacks | β | β | β | $0.0M | $0.0M | $21.5M | $0.0M | $11.3M | $5.0M | $61.6M |
| Dividends paid | $53.3M | $55.2M | $57.2M | $59.0M | $60.7M | $62.2M | $63.4M | $0.0M | $0.0M | β |
| Dividends and buybacks | $53.3M | $55.2M | $57.2M | $59.0M | $60.7M | $83.8M | $63.4M | $11.3M | $5.0M | $61.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $91.6M | $82.8M | $102M | $118M | $264M | $185M | $121M | $147M | $107M | $168M |
| Current assets | $415M | $527M | $508M | $516M | $572M | $546M | $509M | $572M | $557M | $576M |
| Current liabilities | $101M | $184M | $163M | $149M | $162M | $191M | $189M | $217M | $193M | $170M |
| Inventory | β | β | β | β | β | β | β | β | β | $16.8M |
| Property and equipment, net | $13.5M | $13.5M | $12.9M | $28.8M | β | β | β | β | β | β |
| Goodwill | $44.4M | $51.1M | $51.1M | $51.1M | $51.1M | $74.8M | $75.5M | $75.5M | $75.5M | $79.8M |
| Intangible assets | $14.4M | $30.9M | $26.5M | $22.4M | $18.2M | $20.8M | $15.9M | $12.1M | $9.4M | $7.0M |
| Total assets | $528M | $676M | $693M | $723M | $785M | $780M | $721M | $791M | $803M | $794M |
| Total liabilities | $190M | $276M | $252M | $262M | $315M | $332M | $303M | $334M | $303M | $284M |
| Shareholders' equity | $339M | $400M | $441M | $460M | $470M | $445M | $418M | $457M | $500M | $510M |
| Margins | ||||||||||
| Gross margin | 14.3% | 13.5% | 11.7% | 12.4% | 15.2% | 14.0% | 11.4% | 12.8% | 13.3% | 13.0% |
| Net margin | 5.0% | 4.7% | 4.2% | 3.5% | 5.6% | 3.0% | 2.0% | 2.3% | 2.3% | 3.2% |
| FCF margin | 2.3% | 0.1% | 3.7% | 4.8% | 12.1% | 1.9% | β0.8% | 2.3% | 1.4% | 7.6% |
| Returns | ||||||||||
| Return on equity | 22.8% | 23.9% | 19.9% | 14.3% | 21.2% | 10.6% | 7.9% | 8.8% | 8.3% | 11.7% |
| Return on assets | 14.6% | 14.7% | 12.2% | 9.1% | 13.1% | 6.2% | 4.6% | 5.1% | 5.0% | 7.4% |
| Return on tangible equity | 27.6% | 27.7% | 23.0% | 16.7% | 24.6% | 13.9% | 10.5% | 10.4% | 9.5% | 13.9% |
| Growth | ||||||||||
| Revenue growth | β | 19.1% | 7.6% | β8.1% | β4.4% | β6.7% | 2.9% | β1.1% | 2.7% | 7.1% |
| Net income growth | β | 14.0% | β5.3% | β22.7% | 52.8% | β50.8% | β29.5% | 12.1% | 2.8% | 49.6% |
| EPS growth | β | 13.3% | β5.9% | β22.3% | 51.7% | β50.8% | β29.2% | 13.0% | 1.9% | 52.8% |
| FCF growth | β | β93.8% | 3,262.8% | 18.8% | 138.6% | β85.2% | β142.6% | β | β35.8% | 468.7% |
| Share count change | β | 1.2% | 0.4% | β0.0% | 0.3% | 0.2% | β0.8% | β0.0% | β0.5% | β1.3% |
| Financial health | ||||||||||
| Current ratio | 4.1x | 2.9x | 3.1x | 3.5x | 3.5x | 2.9x | 2.7x | 2.6x | 2.9x | 3.4x |
| Quick ratio | 4.1x | 2.9x | 3.1x | 3.5x | 3.5x | 2.9x | 2.7x | 2.6x | 2.9x | 3.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% | 0.4% | 0.3% |
| Stock comp / revenue | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% | 0.5% | 0.5% | 0.5% | 0.5% | 0.7% |
| Payouts / FCF | 148.3% | 2,474.0% | 76.2% | 66.1% | 28.5% | 266.6% | β | 29.6% | 20.5% | 44.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 4.0 | 6.0 | 6.0 | 2.0 | 3.0 | 6.0 | 7.0 | 7.0 |
| Accruals ratio | 6.8% | 13.4% | 0.5% | β4.1% | β15.7% | 1.5% | 5.7% | β0.7% | 1.1% | β10.8% |
Source: SEC EDGAR XBRL filings (CIK 0000731012). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.